Ann: Hainan Invitation to discuss Market Entry into China, page-29

I am not sure what GTG will get out of China.

The SNP sequences that are associated with increased risk of non-familial breast cancer are publically available, so are the risk prediction models.

Linking these two, just needs personal medical and lifestyle data, from patients in the Han population who are BRCA negative - all this can be done by competent Chinese medical scientists and medical practitioners.
I cannot see where GTG fits in - selling Brevagen kits to the Chinese is not possible, the Brevagen panel of SNPs has been tested on Caucasian and African American women, but not Han women ........ yet

In addition, the Chinese are not known for their loyal adherence to patents.